Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Progesterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 4/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Progesterone SCHEMBL3931579 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL15493962 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL16305628 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL14546167 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL13752811 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL7900795 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL23568915 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL9120521 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL6661427 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| Progesterone SCHEMBL20342344 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110208442-A | A kind of method of the drug concentration of progesterone in detection biological sample | 国科卓越(北京)医药科技研究有限公司 | 2019-09-06 | — | — | CN | claimed |
| CN-1615887-A | Progesterone membrane agent and its preparing method | BOAI MEDICINE SCIENCE AND TECH (CN) | 2005-05-18 | — | — | CN | claimed |
| CN-118184642-A | Aromatic ring system heterocycle compound, and pharmaceutical composition and application thereof | 中国药科大学 | 2024-06-14 | — | — | CN | disclosed |
| EP-3426285-B1 | FORMULATIONS AND DOSES OF PEGYLATED URICASE | CARTESIAN THERAPEUTICS INC (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117886734-A | Heterocyclic amide compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-04-16 | — | — | CN | disclosed |
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | CHENGDU ANTICANCER BIOSCIENCE LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| WO-2024011948-A1 | HIGH-EFFICIENCY LEVONORGESTREL-DEGRADING STRAIN AND USE THEREOF | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 2024-01-18 | — | — | WO | disclosed |
| CN-117257836-A | Conjugated estrogens-progesterone compound composition for vagina and preparation | 新疆新姿源生物制药有限责任公司 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023084039-A1 | ASSESSMENT OF GR CELLULAR SIGNALING PATHWAY ACTIVITY USING MATHEMATICAL MODELLING OF TARGET GENE EXPRESSION | INNOSIGN B.V. (NL) | 2023-05-19 | — | — | WO | disclosed |
| US-20230119226-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230107561-A1 | METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT | SELECTA BIOSCIENCES, INC. (US) | 2023-04-06 | — | — | US | disclosed |
| US-6306914-B1 | DRUG DELIVERY FOR PROGESTIN | COLUMBIA LABORATORIES, INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010031747-A1 | Progestin therapy for maintaining amenorrhea | COLUMBIA LABORATORIES (BERMUDA) LIMITED (BM) | 2001-10-18 | — | — | US | disclosed |
| CN-1263558-A | Yeast strain with interrupted ATF2 gene and application thereof | HOECHST MARION ROUSSEL INC (FR) | 2000-08-16 | — | — | CN | disclosed |
| US-6096338-A | MIXTURE OF A DIGESTIBLE OIL AND SURFACTANTS | R. P. SCHERER CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-5645856-A | Delivery systems for hydrophobic drugs | R. P. SCHERER CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0750495-A1 | DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS | R.P. Scherer Limited (GB) | 1997-01-02 | — | — | EP | disclosed |
| WO-1995024893-A1 | DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS | R.P. SCHERER LIMITED (GB) | 1995-09-21 | — | — | WO | disclosed |
| US-5215916-A | Altered cysteine 656 in sequence identification number 5 which contains 795 amino acids with glycine or serine | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 1993-06-01 | — | — | US | disclosed |
| WO-1992022567-A1 | SUPER GLUCOCORTICOID RECEPTORS: RECEPTORS WITH INCREASED AFFINITY AND SPECIFICITY FOR GLUCOCORTICOID STEROIDS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100068-A1 | METHODS COMPRISING ADMINISTRATION OF A GLUCOCORTICOID RECEPTOR AGONIST AND AN INHIBITOR OF CALCINEURIN | PPP3R1, CHP1, NR3C1 | PGR 402/4885CYP3A4 3964/4885LMNA 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.